Our findings indicate that ITH may be an important biomarker for the prognosis and characterisation of PRAD and that the ITH-related gene MYLK2 may serve as a novel target for the treatment of PRAD patients. This evidence concerns the gene MYLK2 and prostate adenocarcinoma.